QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
NCT03647423
Withdrawn
QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Chordoma, Unresectable Malignant Neoplasm
Register for Updates
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03574649
Withdrawn
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Non Small Cell Lung Cancer
Register for Updates
QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03563144
Withdrawn
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
NCT00003042
Active Not Recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and stem cell transplantation work in treating patients with stage IIIB breast cancer.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/17/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Breast Cancer
Register for Updates
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
NCT01871766
Active Not Recruiting
This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy. PRIMARY OBJECTIVE: * Estimate event-free survival for intermediate risk participants treated with vincristine, dactin... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/17/2025
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida +3 locations
Conditions: Rhabdomyosarcoma
Register for Updates
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
NCT03467386
Recruiting
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and c... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
02/17/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Myeloid Leukemia
Register for Updates
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT02625480
Active Not Recruiting
The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). As of October 2022, no further patients with acute B-cell Acute Lymphoblastic Leukemia (ALL) will be asked to join the study. The study remains open for recruitment for patients that have B-cell No... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/13/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +29 locations
Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
NCT02298348
Active Not Recruiting
This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamid... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
02/13/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +11 locations
Conditions: Neuroblastoma
Register for Updates
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964
Completed
This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan. * To find the highest dose of DFMO that can be given with celecoxib, cyclophosphamide and topotecan without causing severe side effects. * To find out the side effects seen by giving DFMO at different dose levels with celecoxib, cyclophosphamide and topotecan. * To measure the levels of DFMO in the blood at different dose levels. * To determine if... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
02/13/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +12 locations
Conditions: Neuroblastoma
Register for Updates
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
NCT04304144
Completed
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/12/2025
Locations: Research Site, Stanford, California +2 locations
Conditions: AL Amyloidosis
Register for Updates
Siplizumab for Sickle Cell Disease Transplant
NCT06078696
Recruiting
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : * To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug * To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of th... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/11/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Anemia, Sickle Cell
Register for Updates
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
NCT01415882
Active Not Recruiting
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates